Combined FISH and IHC identifies patients with rare ALK Fusions that respond to crizotinib

(International Association for the Study of Lung Cancer) The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news